Efficacy of ferrous bis-glycinate versus ferrous glycine sulfate in the treatment of iron deficiency anemia with pregnancy: a randomized double-blind clinical trial

2018 ◽  
Vol 32 (24) ◽  
pp. 4139-4145 ◽  
Author(s):  
Ahmed M. Abbas ◽  
Safaa A. Abdelbadee ◽  
Ahmed Alanwar ◽  
Sayed Mostafa
1987 ◽  
Vol 46 (6) ◽  
pp. 1029-1034 ◽  
Author(s):  
V R Gordeuk ◽  
G M Brittenham ◽  
M Hughes ◽  
L J Keating ◽  
J J Opplt

2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Lu Ding ◽  
Lulin Xu ◽  
Yanxia Jin ◽  
Yongchang Wei ◽  
Yunbao Pan ◽  
...  

Shengxuening (SXN) tablet is extracted from the excrement of the silkworm and has effects on hematopoiesis. The main components of SXN are chlorophyll derivatives and sodium iron chlorophyllin (SIC). The present study aims to investigate the efficiency and safety of SXN on iron deficiency anemia. This phase IV, multicenter, open-label, randomized clinical trial was conducted in 31 hospitals in China from June 2001 to April 2002. Adults and children were randomly divided into low-dose (L-SXN), medium-dose (M-SXN), and high-dose (H-SXN) groups, respectively. The course of treatment was 1 month. Peripheral hemogram levels and iron status were examined before and after treatment. Adults in all three dose groups demonstrated a significant increase in hemoglobin (HGB) concentration. Children who received SXN treatment in medium and high doses also demonstrated increased HGB concentration. Reticulocyte counts increased at the end of treatment in the M-SXN and H-SXN adult groups and in the M-SXN child group. For both children and adults, SXN in the three dose groups was found to significantly elevate red blood cell level, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. The total effective rate in the SXN-treated group reached 84.8%. The incidence of adverse events was 4.07%. The most common side effects were nausea (2.83%), diarrhea (0.74%), and rash (0.25%). SXN was proved to be efficient and safe for adults and children with iron deficiency anemia.


2021 ◽  
Vol 12 (4) ◽  
pp. 56-61
Author(s):  
Bharti Tiwari ◽  
Amar Singh Tiwari ◽  
Satish Chand Gupta

Anemia is a major health problem in India. Yet, a comprehensive plan of action to combat this public health problem has been still missing. There are few existing plans for the control of Iron Deficiency Anemia regarding children and pregnant women and lactating mothers. Iron deficiency is the result of long-term negative iron balance. Iron deficiency anemia (IDA) should be regarded as a subset of iron deficiency, that is, it represents the extreme lower end of the distribution of iron deficiency. Treatment options include oral and intravenous iron therapy; however, the efficacy of oral iron is limited in certain gastrointestinal conditions, such as inflammatory bowel disease, celiac disease, and autoimmune gastritis. So that ameliorate comparative clinical trial was taken with Ayurveda formulation for the diagnosis and treatment of iron deficiency anemia (IDA) with special reference to Pandu Roga. Overall, in the study Navayas Louha was found to have 76.53% and of Nisha Louha was found to have 69.33% clinical efficacy. The study showed that trial clinical efficacy of Navayas Louha syrup is better than Nisha Louha syrup in the management of iron deficiency anemia in Indian children.


Sign in / Sign up

Export Citation Format

Share Document